Module 1: Immuno-oncology: A snapshot of mechanism, progress, limitations and unmet need

Overview

Welcome to the first module in this six-part course on immune checkpoint inhibitors (ICIs).

ICIs have revolutionised treatment for many cancers, particularly in settings where traditional cytotoxic chemotherapy has limited impact. One of the most important features of ICIs is the potential for durable disease control in subsets of patients with unmet need.

However, first-generation ICIs run out of track with immunologically cold or resistant tumours, which applies to large populations of patients. This module will make you fluent in why. You will understand what durable benefit looks like in practice, how to define an immunologically 'cold' tumour and be able to explain how this differs from an immunologically resistant tumour. 

By the end of Module 1, you should be able to:

  • Explain the the biology of immune checkpoints and the first-generation drugs that can inhibit their function.

  • Recognise the clinical importance of ICI, including its potential for durable disease control.

  • Define immunologically cold tumours and distinguish immune-desert from immune-excluded phenotypes.

  • Distinguish cold tumours from ICI-resistant disease.

  • Recognise key clinical settings of unmet need in cold and ICI-resistant disease.

  • Address common misconceptions about cold and ICI-resistant tumours.

This module should take you approximately one hour to complete.

Deleting Course Review

Are you sure? You can't restore this back

Course Access

This course is password protected. To access it please enter your password below: